Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | TET3 | O43151 | 1/20 | 0.61 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.61 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.61 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.61 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.61 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.61 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503291 | 0.96 | KMT2A (0.65) | KMT2ATET3FBXL19CXXC5TET1 | |
| SCHEMBL503877 | 0.95 | KMT2A (0.63) | KMT2ATET3FBXL19CXXC5TET1 | |
| SCHEMBL21874269 | 0.95 | KMT2A (0.63) | KMT2ATET3FBXL19CXXC5TET1 | |
| SCHEMBL301027 | 0.93 | KMT2A (0.64) | KMT2ATET3FBXL19CXXC5TET1 | |
| Formic Acid SCHEMBL27562726 | 0.90 | KMT2A (0.59) | KMT2ATET3FBXL19CXXC5TET1 | |
| SCHEMBL29262920 | 0.86 | CYP2C19 (0.60) | KMT2ATET3FBXL19CXXC5TET1 | |
| SCHEMBL31001015 | 0.86 | KMT2A (0.52) | KMT2ATET3FBXL19CXXC5TET1 | |
| SCHEMBL21874196 | 0.85 | KMT2A (0.57) | KMT2ATET3FBXL19CXXC5TET1 | |
| SCHEMBL16058193 | 0.85 | KMT2A (0.57) | KMT2ATET3FBXL19CXXC5TET1 | |
| SCHEMBL11096445 | 0.85 | KMT2A (0.57) | KMT2ATET3FBXL19CXXC5TET1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-20190119200-A1 | TERTIARY AMIDES AND METHOD OF USE | ABBVIE PHARMACEUTICAL TRADING (SHANGHAI) CO., LTD. (CN) | 2019-04-25 | — | — | US | disclosed |
| US-10118916-B2 | Modulators of cystic fibrosis transmembrane conductance regulator protein | ABBVIE S.Á.R.L. (LU) | 2018-11-06 | — | — | US | disclosed |
| WO-2017187321-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | AbbVie S.à.r.l. (LU) | 2017-11-02 | — | — | WO | disclosed |
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | ABBVIE S.Á.R.L. (LU) | 2017-10-26 | — | — | US | disclosed |
| WO-2017177004-A1 | TERTIARY AMIDES AND METHOD OF USE | ABBVIE INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| EP-1318988-A2 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) | Sepracor, Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. | 2003-03-13 | — | — | US | disclosed |
| WO-2002022572-A2 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) | SEPRACOR, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| US-6124354-A | TREATMENT OF URINARY INCONTINENCE OR IRRITABLE BOWEL SYNDROME | PHARMACIA & UPJOHN AB (SE) | 2000-09-26 | — | — | US | disclosed |
| EP-0923536-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | Pharmacia & Upjohn Aktiebolag (SE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998004517-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | PHARMACIA & UPJOHN AB (SE) | 1998-02-05 | — | — | WO | disclosed |
| EP-0618900-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1997-03-12 | — | — | EP | disclosed |
| US-5519034-A | ANALGESICS | THE BOOTS COMPANY PLC (GB) | 1996-05-21 | — | — | US | disclosed |
| EP-0618900-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS. | BOOTS CO PLC (GB) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993013073-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINES AND THEIR USE AS THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | KMT2A 124/4885TET3 838/4885FBXL19 2320/4885 |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SLC6A2, OPRL1, SLC18A2 | KMT2A 2763/4885TET3 4556/4885FBXL19 4604/4885 |
| US-20170305891-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN | CFTR, CHRM2, CHRM1 | KMT2A 4803/4885TET3 4879/4885FBXL19 4619/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | KMT2A 124/4885TET3 838/4885FBXL19 2320/4885 |
| US-10118916-B2 | Modulators of cystic fibrosis transmembrane conductance regulator protein | CFTR, CHRM2, CHRM1 | KMT2A 4803/4885TET3 4879/4885FBXL19 4619/4885 |
| US-20190119200-A1 | TERTIARY AMIDES AND METHOD OF USE | LPAR1, LPAR3, LPAR2 | KMT2A 1886/4885TET3 4866/4885FBXL19 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.